Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement

Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement

Relationships and Activities. The Council of Experts was supported by AstraZeneca.

Bibliographic Details
Main Authors: S. N. Tereshchenko, M. V. Shestakova, F. T. Ageev, G. R. Galstyan, A. S. Galyavich, M. G. Glezer, I. V. Zhirov, Yu. A. Karpov, Zh. D. Kobalava, S. T. Matskeplishvili
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC  2020-06-01
Series:Российский кардиологический журнал
Subjects:
heart failure with reduced ejection fraction
dapa-hf trial
dapagliflozin
Online Access:https://russjcardiol.elpub.ru/jour/article/view/3919

Internet

https://russjcardiol.elpub.ru/jour/article/view/3919

Similar Items